COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

Citing Articles

The Prognostic Value of Circulating Cytokines and Complete Blood Count-Based Inflammatory Markers in COVID-19 Patients With Atrial Fibrillation.

Tcholadze G, Pantsulaia I, Ratiani L, Kopaleishvili L, Bolotashvili T, Jorbenadze A Cardiol Res. 2025; 16(2):153-160.

PMID: 40051670 PMC: 11882233. DOI: 10.14740/cr2027.

Haematological Manifestations of SARS-CoV-2: Insights into Erythropoiesis, Hepcidin Regulation, and Cytokine Storm.

Parham E, Ahmad M, Falasca M Int J Mol Sci. 2025; 26(3).

PMID: 39940645 PMC: 11817086. DOI: 10.3390/ijms26030874.

The prevalence of thromboembolic events among COVID-19 patients admitted to a single centre intensive care unit (ICU): an epidemiological study from a Malaysian population.

Mansor N, Abdul Halim Zaki I, Kiok L, Seng E, Ravi T, Pathmanathan M J Pharm Policy Pract. 2025; 18(1):2449044.

PMID: 39917475 PMC: 11800336. DOI: 10.1080/20523211.2024.2449044.

Age and clinical spectrum of COVID-19 are associated with safety of transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study.

Wang Z, Yang T, Zhang L, Makamure J, Hong W, Liang B J Gastrointest Oncol. 2025; 15(6):2642-2655.

PMID: 39816043 PMC: 11732337. DOI: 10.21037/jgo-24-527.

The association between baseline viral load and long-term risk in patients with COVID-19 in Hong Kong: a territory-wide study.

Tromp J, Wong M, Ouwerkerk W, Wu M, Ren Q, Chandramouli C Sci Rep. 2024; 14(1):30644.

PMID: 39730325 PMC: 11680948. DOI: 10.1038/s41598-024-65764-0.

References

Aujesky D, Roy P, Verschuren F, Righini M, Osterwalder J, Egloff M . Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011; 378(9785):41-8. DOI: 10.1016/S0140-6736(11)60824-6. View

Arcelus J, Candocia S, Traverso C, Fabrega F, Caprini J, Hasty J . Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost. 1991; 17 Suppl 3:313-8. View

Schunemann H, Cushman M, Burnett A, Kahn S, Beyer-Westendorf J, Spencer F . American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018; 2(22):3198-3225. PMC: 6258910. DOI: 10.1182/bloodadvances.2018022954. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Wong R, Wu A, To K, Lee N, Lam C, Wong C . Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003; 326(7403):1358-62. PMC: 162124. DOI: 10.1136/bmj.326.7403.1358. View

Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R . Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013; 368(6):513-23. DOI: 10.1056/NEJMoa1111096. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

Libby P, Simon D . Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103(13):1718-20. DOI: 10.1161/01.cir.103.13.1718. View

10.

Lippi G, Lavie C, Sanchis-Gomar F . Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020; 63(3):390-391. PMC: 7127395. DOI: 10.1016/j.pcad.2020.03.001. View

11.

Xiong T, Redwood S, Prendergast B, Chen M . Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020; 41(19):1798-1800. PMC: 7454513. DOI: 10.1093/eurheartj/ehaa231. View

12.

Schulman S . Inhibition of warfarin activity by ribavirin. Ann Pharmacother. 2002; 36(1):72-4. DOI: 10.1345/aph.1A181. View

13.

Whitaker A, Bunce I, Graeme E . Disseminated intravascular coagulation and acute renal failure in influenza A2 infection. Med J Aust. 1974; 2(6):196-201. DOI: 10.5694/j.1326-5377.1974.tb70703.x. View

14.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

15.

Smith B, Yogaratnam D, Levasseur-Franklin K, Forni A, Fong J . Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012; 141(5):1327-1336. DOI: 10.1378/chest.11-1396. View

16.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

17.

TALLEY N, Assumpcao C . Disseminated intravascular clotting complicating viral pneumonia due to influenza. Med J Aust. 1971; 2(15):763-6. DOI: 10.5694/j.1326-5377.1971.tb92529.x. View

18.

Umapathi T, Kor A, Venketasubramanian N, Tchoyoson Lim C, Pang B, Yeo T . Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004; 251(10):1227-31. PMC: 7088071. DOI: 10.1007/s00415-004-0519-8. View

19.

Ikesaka R, Delluc A, Le Gal G, Carrier M . Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thromb Res. 2014; 133(4):682-7. DOI: 10.1016/j.thromres.2014.01.021. View

20.

Lippi G, Plebani M, Henry B . Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020; 506:145-148. PMC: 7102663. DOI: 10.1016/j.cca.2020.03.022. View